MAXOLON

Pre-Launch

metoclopramide hydrochloride

ANDAORALTABLET

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

MAXOLON (metoclopramide hydrochloride) by Pfizer is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Approved for vomiting associated with emetogenic cancer chemotherapy, postoperative nausea, vomiting in those circumstances where nasogastric suction is undesirable.

Drug data last refreshed 1mo ago

Mechanism of Action

CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…

Worked on MAXOLON at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

MAXOLON

Mechanism of Action

Indications (3)